Broomfield, CO, April 24, 2002 -- Unigen Pharmaceuticals, Inc., a leading natural products research and development facility and proprietary ingredients supplier named Bruce P. Burnett, Ph.D., to the position of director of discovery and development.
“We instantly connected with Bruce and believe he will be instrumental to the continuing success of Unigen Pharmaceuticals, Inc.,” said Derek Hall, chief executive officer of Unigen Pharmaceuticals. “His experience and expertise in biochemistry, genomics, molecular biology, bacteriology and protein chemistry easily qualify him for his new responsibilities.”
Prior to joining Unigen, Burnett worked for a variety of biotechnology and pharmaceutical companies including Sulzer Biologics, Inc., Vitro Diagnostics, Inc., Sangamo BioSciences, Inc., Cytokine Sciences, Inc. and Enzyco, Inc.
Burnett received his BS degrees in Biology and Chemistry from Eastern Washington University in Cheney, WA, and his MS and Ph.D. degrees from Yale University in New Haven, CT.
Unigen is a world leader in nutraceutical and cosmeceutical research committed to health and wellness. The company is dedicated to the discovery of botanically derived therapeutic compounds that address specific disease states with a focus to improve the quality of life. Unigen and sister company Aloecorp are subsidiaries of the Unigen Group of companies, each identifying and studying the unique and potential medicinal compounds found in botanicals, and then formulating proprietary ingredients for use in cosmeceutical, nutraceutical and pharmaceutical products.